Endurant Capital Management LP Viridian Therapeutics, Inc.\De Transaction History

Endurant Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$9.55 - $19.0 $794,722 - $1.58 Million	-83,217 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $264,727 - $329,214	15,767 Added 23.38%	83,217 $1.54 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $1.06 Million - $1.45 Million	67,450 New	67,450 $1.33 Million

143

62.1M

160K

354K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $485M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.